Zacks Investment Research lowered shares of Cerulean Pharma Inc. (NASDAQ:CERU) from a strong-buy rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Cerulean Pharma Inc. is a clinical-stage oncology-focused company. The Company manufactures therapeutics in the areas of oncology, cardiovascular, autoimmune, and inflammatory diseases as well as tumor cells. Cerulean Pharma Inc. is based in Cambridge, Massachusetts. “

Several other brokerages have also recently commented on CERU. Leerink Swann cut shares of Cerulean Pharma from an outperform rating to a market perform rating and dropped their price target for the stock from $8.00 to $1.50 in a research report on Thursday, August 18th. Janney Montgomery Scott cut Cerulean Pharma from a buy rating to a neutral rating in a research note on Thursday, August 18th. Roth Capital reissued a buy rating and issued a $2.50 price target (down previously from $9.00) on shares of Cerulean Pharma in a research note on Thursday, August 18th. Wedbush cut Cerulean Pharma from an outperform rating to a neutral rating in a research note on Thursday, August 18th. Finally, Canaccord Genuity reissued a buy rating and issued a $20.00 price target (down previously from $29.00) on shares of Cerulean Pharma in a research note on Sunday, August 21st. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $7.78.

Analyst Recommendations for Cerulean Pharma (NASDAQ:CERU)

Cerulean Pharma (NASDAQ:CERU) opened at 0.6808 on Tuesday. Cerulean Pharma has a 12-month low of $0.67 and a 12-month high of $4.33. The stock’s market cap is $18.64 million. The company has a 50-day moving average of $0.96 and a 200 day moving average of $2.14.

Cerulean Pharma (NASDAQ:CERU) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.08. Equities analysts anticipate that Cerulean Pharma will post ($1.58) earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Bridgeway Capital Management Inc. boosted its stake in shares of Cerulean Pharma by 97.4% in the second quarter. Bridgeway Capital Management Inc. now owns 202,623 shares of the company’s stock valued at $430,000 after buying an additional 100,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cerulean Pharma by 43.8% in the second quarter. Vanguard Group Inc. now owns 542,631 shares of the company’s stock valued at $1,151,000 after buying an additional 165,181 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Cerulean Pharma by 33.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 62,251 shares of the company’s stock valued at $169,000 after buying an additional 15,525 shares during the last quarter. 33.19% of the stock is owned by institutional investors and hedge funds.

Cerulean Pharma Company Profile

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

5 Day Chart for NASDAQ:CERU

Receive News & Stock Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related stocks with our FREE daily email newsletter.